Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer-Reference-Cited by-同舟云学术

Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer

Published:2023-10 Issue:10 Volume:9 Page:e20463
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Fukuda Kiyoko,Katsurada Naoko,Kawa Yoshitaka,Satouchi Miyako,Kaneshiro Kazumi,Matsumoto Masataka,Takamiya Rei,Hatakeyama Yukihisa,Dokuni Ryota,Matsumura Kanoko,Katsurada Masahiro^ORCID,Nakata Kyosuke^ORCID,Yoshimura Sho,Tachihara Motoko^ORCID

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference24 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA A Cancer J. Clin.,2018

2. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N. Engl. J. Med.,2018

3. CASPIAN investigators, Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019

4. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival;Sumikawa;Am. J. Respir. Crit. Care Med.,2008

5. Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival;Nishino;Eur. J. Radiol.,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy + ICIs in extensive-stage small-cell lung cancer: risk of interstitial lung disease;Reactions Weekly;2023-10-28